Randomized controlled trials of GLP-1 RAs (such as exenatide) in a cohort of PD patients have reported a good overall tolerability and indicated that the most common adverse events are mild nausea, appetite suppression, and modest weight loss [53]. Here, GLP1R is linked to Parkinson disease.